NW
BPMC

NewEdge Wealth’s Blueprint Medicines BPMC Stock Holding History

NewEdge Wealth’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,625
Closed -$321K – 970
2025
Q1 		$321K Buy
3,625
+179
+5% +$17.5K 0.01% 759
2024
Q4 		$301K Buy
3,446
+67
+2% +$6.14K 0.01% 764
2024
Q3 		$313K Buy
3,379
+64
+2% +$6.36K 0.01% 717
2024
Q2 		$357K Hold
3,315
– – 0.01% 617
2024
Q1 		$355K Sell
3,315
-250
-7% -$21.4K 0.01% 631
2023
Q4 		$329K Sell
3,565
-550
-13% -$35.6K 0.01% 599
2023
Q3 		$207K Sell
4,115
-550
-12% -$29.4K 0.01% 616
2023
Q2 		$295K Sell
4,665
-825
-15% -$44.9K 0.01% 550
2023
Q1 		$247K Buy
+5,490
New +$247K 0.01% 543

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NewEdge Wealth's BPMC Position: Q2 2025 in Review

NewEdge Wealth sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 3,625 shares — an estimated $321K sold.

NewEdge Wealth first reported a position in BPMC in Q1 2023 and held it in 9 quarters. The position peaked at $357K in Q2 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • NewEdge Wealth reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • NewEdge Wealth sold 3,625 Blueprint Medicines shares in Q2 2025, an estimated $321K.
  • NewEdge Wealth first reported a position in Blueprint Medicines in Q1 2023 and held it in 9 quarters.
  • NewEdge Wealth's Blueprint Medicines position peaked at $357K in Q2 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on NewEdge Wealth's 13F filing for Q2 2025, filed 11 Aug 2025.